← Back to Clinical Trials
Recruiting Phase 3 NCT06966245

NCT06966245 External Mastalgia-oil Versus Placebo in Premenopausal Women With Severe Mastalgia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06966245
Status Recruiting
Phase Phase 3
Sponsor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Condition Mastalgia
Study Type INTERVENTIONAL
Enrollment 190 participants
Start Date 2025-06-08
Primary Completion 2027-06-01

Trial Parameters

Condition Mastalgia
Sponsor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 190
Sex FEMALE
Min Age 18 Years
Max Age 60 Years
Start Date 2025-06-08
Completion 2027-06-01
Interventions
mastalgia-oilMastalgia-oil placebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is a single-center, double-blind, randomized clinical trial to explore the efficacy and safety of external mastalgia-oil versus placebo in premenopausal women with severe mastalgia.

Eligibility Criteria

Inclusion Criteria: * Premenopausal females aged ≥ 18 years old * Pre-existing regular menstrual cycle (28 ± 5 days) with mastalgia lasting for at least 6 consecutive menstrual cycles; with severe mastalgia \[visual analog scale (VAS) score ≥ 4 for at least 7 days\] and without chest wall pain in the baseline menstrual cycle (nonmedicated menstrual cycle) * With breast ultrasound: BI-RADS classification 1-3; if mammography is required: also BI-RADS classification 1-3 * Willingness to follow up and complete required tests; ability to complete questionnaires independently or with assistance * Willingness to use effective contraception (vaginally administered estrogen and hormone-coated IUDs are permitted) prior to study entry, during study participation, and for three months after discontinuation of the drug; negative pregnancy test in females of childbearing potential * Requisite laboratory values:white blood cell count: ≥ 4.0 × 10\^9/L, absolute neutrophil count: ≥ 2 × 10\^9/L, platele

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology